MedPath

Investigating the comparative preventive efficacy and safety of FluGaurd® (a 4-valent recombinant influenza vaccine, produced by Niwad-Pharmed-Salamat company, I.R.Iran), to Vaxigrip® (produced by Sanofi company, France) as the reference product in Healthy volunteers

Phase 3
Conditions
Seasonal Influenza.
Influenza due to certain identified influenza viruses
Registration Number
IRCT20080901001165N61
Lead Sponsor
iwad-Pharmed-Salamat company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
200
Inclusion Criteria

The age of the volunteer is between 18 and 49 years.
The volunteer has general health (through clinical examinations and medical records).
The volunteer or his/her legal guardian must have signed the informed consent form.
The volunteer must be able to keep up with the monitoring programs.

Exclusion Criteria

Have a history of previous vaccinations against influenza strains used in injectable vaccines;
Have a history of allergy to Vaxigrip;
History of chronic use (more than 14 days) immunosuppressive drugs in the last 6 months (in the case of corticosteroids, prednisolone (or its equivalents) in the amount of 0.5 mg per kg of volunteer weight per day. Topical or inhaled steroids usage are free.)
History of any immune system disorders such as Guillain-Barré syndrome and other Masculoscletal disorders;
History of chronic diseases such as cancer, liver and kidney disease, neurological disorders, diabetes;
History of receiving immunoglobulins or other blood products 90 days before the vaccine injection;
Pregnancy;
Lactation.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath